|
KabaFusion, a nationally recognized leader in home infusion, has been selected by GC Biopharma USA as a limited distribution partner to provide Alyglo (Immune Globulin Intravenous, Human-stwk) 10 per cent liquid for adults, 17 years and older, with primary humoral immunodeficiency (PI).
Alyglo is a liquid solution containing 10 per cent immunoglobulin G (100 mg/mL) for intravenous infusion. Alyglo uses its novel proprietary Cation Exchange Chromatography (CEX) in the manufacturing process for removing FXIa to undetectable levels.
“We are pleased to select KabaFusion as a limited distribution partner for Alyglo,” said Woo Jin Lee, chief executive officer of GC Biopharma. “KabaFusion is an innovative leader and national provider of IVIG specialty pharmacy services. KabaFusion’s national reach, expertise in IVIG, and superb patient management make them an ideal partner.”
“We are excited about our partnership with GC Biopharma, and KabaFusion is well-positioned to serve a growing number of patients living with primary immunodeficiency. Our nationwide footprint along with our unmatched commitment to deliver high-quality patient care make us a great partner for this important treatment. We are honored to have been chosen as a limited distribution partner for Alyglo,” said Dr. Sohail Masood, founder and CEO of KabaFusion.
GC Biopharma USA, Inc. is headquartered in Teaneck, New Jersey and established its sales, marketing, and business operations in 2018 to serve customers and patients throughout the US.
KabaFusion is a national provider of essential chronic and acute infusion therapies. The company serves patients in 46 states through its nationwide network of home infusion pharmacies, alternative infusion sites, and home health agencies.
|